Patheon, a provider of contract development and manufacturing services to the global pharmaceutical industry, has appointed Michel Lagarde, principal, JLL Partners, to its board of directors. Lagarde replaces Thomas S. Taylor, managing director, JLL Partners, who is leaving the board.
Patheon Inc. (TSX: PTI), a leading provider of contract development and manufacturing services to the global pharmaceutical industry, is pleased to announce the appointment of Michel Lagarde, Principal, JLL Partners, to its Board of Directors. Mr. Lagarde replaces Thomas S. Taylor, Managing Director, JLL Partners, who is leaving the Board today. Mr. Lagarde will replace Mr. Taylor as the Chairman of Patheon’s Compensation and Human Resources Committee and will be a member of Patheon’s Audit and Corporate Governance Committees.
Mr. Lagarde joined JLL Partners in 2008. He was previously the CEO and CFO of the Domestic Appliances and Personal Care division of Philips Electronics North America. He also held positions as CFO of Philips Electronics Indonesia and Financial Controller of Philips Electronics Hong Kong. Mr. Lagarde currently serves on the Boards of ACE Cash Express and SOS Children’s Villages – USA. He received a B.B.A from European University Antwerp and an Executive Master in Finance and Control from the University of Amsterdam.
Mr. Taylor remains with JLL Partners as Managing Director and is actively involved advising other JLL Partner portfolio companies.
Patheon Inc. (TSX: PTI) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. The company provides the highest quality products and services to approximately 300 of the world’s leading pharmaceutical and biotechnology companies. Its services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid and liquid forms.
The company’s comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. The company’s integrated development and manufacturing network of 10 manufacturing facilities, nine development centers and one clinical trial material packaging facility across North America and Europe, enables customer products to be launched with confidence anywhere in the world.
SOURCE Patheon Inc.